P
Psivant Therapeutics
Psivant Therapeutics is advancing a paradigm shift in biotechnology by pioneering a computation-first approach to drug design
About Psivant Therapeutics
PsiThera, formerly Psivant Therapeutics, is a Watertown, Massachusetts-based biotechnology company that designs oral small-molecule drugs for immune and inflammatory diseases, areas that have historically relied on injected biologics. Its proprietary QUAISAR platform combines physics-based molecular simulation, machine learning and experimental biophysics to model biologically relevant protein motion and find transient, druggable binding pockets that static structure-based methods miss. The company's pipeline targets clinically validated cytokine pathways in the TNF superfamily and beyond, led by an oral TNF-alpha inhibitor and an oral TL1A program, with IL-6 among its initial targets. PsiThera originated as a Roivant spinout and now operates as an independent company.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Watertown, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 50.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, AI Drug Discovery, Techbio, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
Knowledge graph
News
More headlines
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2025 | $48M | $190M | Roivant Sciences · Lightstone Ventures · Eurofarma · YK Bioventures | ↗ |
Growth signals
Latest recorded traffic for Psivant Therapeutics is 600 monthly website visits, down 80.6% over the last three months. Psivant Therapeutics's team grew 60.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Psivant Therapeutics in the Watertown ecosystem
The Psivant Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Lightstone Ventures
Samsara BioCapital
Roivant Sciences
Eurofarma
YK Bioventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Psivant Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Psivant Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









